Khosla Ventures Acquisition Co
Change company Symbol lookup
Select an option...
KVSA Khosla Ventures Acquisition Co
FPI Farmland Partners Inc
HNST Honest Company Inc
ONTF ON24 Inc
ATAI ATAI Life Sciences NV
FTS Fortis Inc
VLO Valero Energy Corp
BBLN+ Babylon Holdings Equity Warrants 21st Oct 2026 *W EXP 10/21/2026
NEGG Newegg Commerce Inc
LTRY Lottery.com Inc
Go

*Nasdaq FSI: *Deficient: Issuer Failed to Meet NASDAQ Continued Listing Requirements

Company profile

Khosla Ventures Acquisition Co. is a blank check company. The Company is formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses. The Company intends to focus its search on market opportunity with differentiated, proprietary technology. The Company has not commenced any operations and has not generated revenues.

Closing Price
$9.81
Day's Change
0.00 (0.00%)
Bid
--
Ask
--
B/A Size
--
Day's High
9.82
Day's Low
9.79
Volume
(Heavy Day)
Volume:
172,786

10-day average volume:
19,311
172,786

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FHS, AXSM and SPRO

1:35 pm ET July 6, 2022 (Accesswire) Print

NEW YORK, NY / ACCESSWIRE / July 6, 2022 / The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. There is no cost to participate in the suit. If you suffered a loss, you have until the lead plaintiff deadline to request that the court appoint you as lead plaintiff.

First High-School Education Group Co., Ltd. (NYSE:FHS)

This lawsuit is on behalf of all persons or entities who purchased FHS American Depositary Shares in or traceable to the Company's March 2021 initial public offering.

Lead Plaintiff Deadline: July 11, 2022

Throughout the class period, First High-School Education Group Co., Ltd. allegedly made materially false and/or misleading statements and/or failed to disclose that: (a) the new rules, regulations and policies to be implemented by the Chinese government following the Two Sessions parliamentary meetings were far more severe than represented to investors and posed a material adverse threat to the Company and its business; (b) contemplated Chinese regulations and rules regarding private education were leading to a slowdown of government approval to open new educational facilities which would have a negative effect on FHS's enrollment and growth; and (c) as a result, representations made in connection with the Company's initial public offering regarding FHS's historical financial and operational metrics and purported market opportunities did not accurately reflect the actual business, operations, and financial results and trajectory of the Company at the time of the initial public offering, and were materially false and misleading and lacked a factual basis.

Learn about your recoverable losses in FHS: https://www.kleinstocklaw.com/pslra-1/first-high-school-education-group-co-ltd-loss-submission-form?id=29582&from=1

Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Class Period: December 30, 2019 - April 22, 2022

Lead Plaintiff Deadline: July 12, 2022

During the class period, Axsome Therapeutics, Inc. allegedly made materially false and/or misleading statements and/or failed to disclose that: (i) Axsome's chemistry, manufacturing, and control ("CMC") practices were deficient with respect to AXS-07, the Company's medicine for the acute treatment of migraine, and its manufacturing process; (ii) as a result, Axsome was unlikely to submit the AXS-07 New Drug Application ("NDA") on its initially represented timeline; (iii) the foregoing CMC issues remained unresolved at the time that the U.S. Food and Drug Administration ("FDA") reviewed the AXS-07 NDA; (iv) accordingly, the FDA was unlikely to approve the AXS-07 NDA; (v) as a result of all the foregoing, Axsome had overstated AXS-07's regulatory and commercial prospects; and (vi) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in AXSM: https://www.kleinstocklaw.com/pslra-1/axsome-therapeutics-inc-loss-submission-form?id=29582&from=1

Spero Therapeutics, Inc. (NASDAQ:SPRO)

Class Period: October 28, 2021 - May 2, 2022

Lead Plaintiff Deadline: July 25, 2022

The SPRO lawsuit alleges Spero Therapeutics, Inc. made materially false and/or misleading statements and/or failed to disclose during the class period that: (i) the data submitted in support of the New Drug Application ("NDA") for the Company's product candidate, Tebipenem HBr, were insufficient to obtain approval from the U.S. Food and Drug Administration ("FDA"); (ii) accordingly, it was unlikely that the FDA would approve the Tebipenem HBr NDA in its current form; (iii) the foregoing would necessitate a significant workforce reduction and restructuring of Spero's operations; and (iv) as a result, the Company's public statements were materially false and misleading at all relevant times.

Learn about your recoverable losses in SPRO: https://www.kleinstocklaw.com/pslra-1/spero-therapeutics-inc-loss-submission-form?id=29582&from=1

The Klein Law Firm, Wednesday, July 6, 2022, Press release picture

Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. If you suffered a loss during the class period and wish to obtain additional information, please contact J. Klein, Esq. by telephone at 212-616-4899 or visit the webpages provided.

J. Klein, Esq. represents investors and participates in securities litigations involving financial fraud throughout the nation. Attorney advertising. Prior results do not guarantee similar outcomes.

CONTACT:

J. Klein, Esq.

Empire State Building

350 Fifth Avenue

59th Floor

New York, NY 10118

jk@kleinstocklaw.com

Telephone: (212) 616-4899

Fax: (347) 558-9665

www.kleinstocklaw.com

SOURCE: The Klein Law Firm





View source version on accesswire.com:

https://www.accesswire.com/707729/The-Klein-Law-Firm-Reminds-Investors-of-Class-Actions-on-Behalf-of-Shareholders-of-FHS-AXSM-and-SPRO



comtex tracking

COMTEX_409774394/2457/2022-07-06T13:35:32

Earnings Calendar and Events Data provided by |Terms of Use| © 2022 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2022. All rights reserved.